Selvigaltin

Selvigaltin (GB1211) is an orally active galectin-3 small molecule inhibitor with an IC50 value of 12 nM in rabbits, showing anti-tumor activity. Selvigaltin decreases galectin-3 levels in the liver and reduces biomarkers of liver function (AST, ALT, bilirubin), inflammation (cells foci) and fibrosis (PSR, SHG), as well as decreasing the mRNA and protein expression of several key inflammation and fibrosis biomarkers (IL6, TGFβ3, SNAI2, collagen) . Selvigaltin restores T-cell activity and induces less tumors and metastasis[1][2][3][4].

Product Specifications

CAS Number

[1978336-95-6]

Product Name Alternative

GB1211

UNSPSC

12352005

Target

Galectin

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/selvigaltin.html

Concentration

10mM

Purity

99.89

Solubility

DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O[C@@H]([C@H](O1)SC2=CN=CC(Br)=C2)[C@](N3C=C(C(C=C4F)=CC(F)=C4F)N=N3)([H])[C@H]([C@H]1CO)O

Molecular Formula

C19H16BrF3N4O4S

Molecular Weight

533.32

References & Citations

[1]Slack RJ, et al. The therapeutic potential of galectin-3 inhibition in fibrotic disease. Int J Biochem Cell Biol. 2021 Jan;130:105881. |[2]Zetterberg Fredrik, et al. Preparation of galactosides as galectins inhibitors. WO2020078808+A1. 2020 April 23.|[3]Comeglio P, et al. The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis. Front Pharmacol. 2024 Jul 31;15:1430109.|[4]Aslanis V, et al. Single‑Dose Pharmacokinetics and Safety of the Oral Galectin‑3 Inhibitor, Selvigaltin (GB1211), in Participants with Hepatic Impairment. Clin Drug Investig. 2024 Oct 2.